Direct comparison shows that mRNA-based diagnostics incorporate information which cannot be learned directly from genomic mutations.

ABSTRACT: BACKGROUND:Compared to the many uses of DNA-level testing in clinical oncology, development of RNA-based diagnostics has been more limited. An exception to this trend is the growing use of mRNA-based methods in early-stage breast cancer. Although DNA and mRNA are used together in breast cancer research, the distinct contribution of mRNA beyond that of DNA in clinical challenges has not yet been directly assessed. We hypothesize that mRNA harbors prognostically useful information independently of genomic variation. To validate this, we use both genomic mutations and gene expression to predict five-year breast cancer recurrence in an integrated test model. This is accomplished first by comparing the feature importance of DNA and mRNA features in a model trained on both, and second, by evalua

SUBMITTER: Ravkin HD 

PROVIDER: S-EPMC7236449 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature